Use of variants of dihydrofolate reductase in gene transfer to produce resistance to methotrexate and trimetrexate.
Bertino
J R
JR
Molecular Pharmacology and Therapeutics Program, Sloan Kettering Institute for Cancer Research, New York, N.Y., USA. bertinoj@mskcc.org
Zhao
S C
SC
Mineishi
S
S
Ercikan-Abali
E A
EA
Banerjee
D
D
D004351:Drug Resistance / Q000235:genetics; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D018014:Gene Transfer Techniques; D014644:Genetic Variation; D008727:Methotrexate / Q000494:pharmacology*; D013762:Tetrahydrofolate Dehydrogenase / Q000235:genetics*; D016597:Trimetrexate / Q000494:pharmacology*
D004791:Enzyme Inhibitors; D013762:Tetrahydrofolate Dehydrogenase; D016597:Trimetrexate; D008727:Methotrexate